Endogenous oxidative stress is believed to play a key role in the pathogenesis of mitochondrial diseases (MD) . In this group of heterogeneous disorders the increased production of radical species caused by compromised mitochondrial respiratory function could affect both mitochondrial and nuclear DNA integrity. The aim of the present study was to assess the basal level of nuclear DNA (nDNA) damage in terms of chromosome and DNA alterations in leukocytes of 13 patients (age range 29±74 years) presenting several forms of MD. A further objective of this work was the evaluation of possible changes in nDNA in a subgroup of patients (10 individuals) before and after a 2 week therapy with ubidecarenone, a coenzyme Q10 analogue. The extent of cytogenetic damage, expressed as chromosome breakage and chromosome loss, was assessed employing the cytokinesis block micronucleus method in cultured peripheral blood lymphocytes, coupled with¯uorescence in situ hybridization analysis using a digoxigenin-labelled pancentromeric DNA probe. A modi®ed version of the single cell gel electrophoresis assay was used to quantify primary and oxidative DNA damage in leukocytes. In MD patients an increased level of chromosome damage, expressed as frequency of micronucleated lymphocytes, was detected in comparison with healthy individuals of corresponding sex, age and lifestyle. The FISH analysis revealed a preferential occurrence of micronuclei arising from loss of whole chromosomes in patients, with no substantial difference in frequencies observed in matched controls. The Comet assay indicated a slightly higher level of primary DNA damage in patients compared with controls and also a difference in oxidative DNA damage, however, this was not statistically signi®cant. Patients receiving ubidecarenone showed a statistically signi®cant reduction in the frequency of micronucleated cells after therapy, while only a slight decrease was observed in the levels of both primary DNA damage and oxidized bases.
Introduction
Mitochondrial diseases (MD) are a wide group of disorders often characterized by impairment in energy production by means of the mitochondrial oxidative phosphorylation (OXPHOS) process. A common presenting feature of mitochondrial syndromes is the involvement of muscle and the central nervous system, tissues greatly relying on oxidative metabolism for their energy supply and so especially susceptible to its impairment (DiMauro and Moraes, 1993) . These rare disorders are usually associated with a delayed age of onset, organ target selectivity and a progressive course. Over 100 point mutations and numerous rearrangements of mitochondrial DNA (mtDNA) have been associated with a wide spectrum of multi-systemic or tissue-speci®c disorders and mutations in nuclear genes responsible for alterations in individual respiratory chain complexes and for defects of intergenomic signalling are now well known (Shoubridge, 2001) . In some cases, as a consequence of the still incomplete knowledge of the underlying molecular defect, it is not possible to detect the exact pathogenetic mutation: in such instances the diagnosis is based on clinical, morphological and biochemical observations.
Primary or nucleus-driven mtDNA mutations are responsible for the observed decline in aerobic ATP production, but they also seem to lead to other important consequences. Indeed, several hypotheses have been proposed to explain the still unknown mechanisms underlying the pathophysiology of cell damage in mitochondrial disease. Among the factors invoked, increased endogenous oxidative stress seems to play a major role. Reactive oxygen species (ROS), such as the superoxide anion and hydrogen peroxide, are generated during the normal respiratory process in mitochondria through reactions with electrons that escape the electron transport chain. Enhanced production of ROS, elicited by OXPHOS defects and not followed by a comparable increase in antioxidant defence, seems to result in further persistent damage to cellular structures, including mtDNA itself and membrane lipids, thus generating a vicious cycle (Wei, 1998; Cassarino et al., 1999) . Second, both nuclear DNA (nDNA) and mtDNA mutations, originating as a consequence of oxidative stress, may contribute to the initiation and progression of mitochondrial diseases and may also account for the great variation in clinical phenotypes. Enhanced production of radical species resulting from failure of the mitochondrial respiratory chain may also induce additional nDNA damage even in peripheral target tissues like blood cells. In fact, peripheral non-dividing leukocytes can be regarded as a valid indicator of the overall level of oxidative damage in the body.
This work aimed at assessing background levels of nDNA damage in peripheral leukocytes of 13 patients suffering from various forms of MD. Cytogenetic alterations, in terms of chromosome breakage and chromosome loss, were evaluated employing the cytokinesis block micronucleus method (CBMN assay) in cultured peripheral blood lymphocytes, followed bȳ uorescence in situ hybridization (FISH) using a digoxigeninlabelled alphoid DNA probe speci®c for the centromere of all human chromosomes. Micronuclei (MN) may originate from acentric chromosome fragments or whole chromosomes lagging behind during cell division. The CBMN assay, especially when coupled to FISH analysis, is an effective tool for 3 To whom correspondence should be addressed. Tel: +39 050 836223; Fax: +39 050 551290; Email: l.migliore@geog.unipi.it Evaluation of cytogenetic and DNA damage in mitochondrial disease patients: effects of coenzyme Q10 therapy 1 assessing cytogenetic alterations (Norppa and Falk, 2003) . This methodology was successfully applied to detect increased rates of chromosome damage in patients with degenerative diseases such as Alzheimer's disease (Migliore et al., 1997; Trippi et al., 2001 ), Parkinson's disease and cancer (Bolognesi et al., 2002) .
In recent years, single cell gel electrophoresis (SCGE), also known as the Comet assay, a rapid, simple and sensitive device, was introduced to quantify genomic damage at the individual cell level and speci®cally for detecting DNA strand breaks (Singh et al., 1988) . The Comet assay has found increasing applications in the assessment of DNA damage in human biomonitoring studies (Kassie et al., 2000; Moller et al., 2000) , in subjects affected by various pathological conditions (Tice et al., 1992; Collins et al., 1998; Harangi et al., 2002; Andreassi et al., 2002) and in the investigation of the protective effects of antioxidant supplementation (Duthie et al., 1996; Sardas et al., 2001; Sierens et al., 2001; Kan et al., 2002) . In order to obtain speci®c information about oxidative DNA damage, in parallel with the cytogenetic study we performed the alkaline SCGE procedure, modi®ed with digestion of the DNA by two bacterial repair endonucleases , on leukocytes. These lesion-speci®c enzymes are endonuclease III (endo III), which recognizes oxidized pyrimidines, and formamidopyrimidine-DNA glycosylase (fpg), speci®c for altered purines, particularly 8-oxodeoxyguanosine (8-oxodG), the most common biological marker of oxidative stress in DNA.
In a subgroup of patients (n = 10) the extent of nDNA damage was assessed before and after a 2 week therapy with coenzyme Q10 (CoQ10). No proposed therapeutic approach is effective for MD, but some trials have used the administration of a mixture of free radical scavengers, such as CoQ10, in order to avoid further cellular damage and worsening symptoms (DiMauro et al., 2000; Chan et al., 1998; Abe et al., 1999; Chariot et al., 1999) . CoQ10 is known to improve mitochondrial respiratory functionality, probably acting not only as an essential cofactor of the mitochondrial electron transport chain, but also as an ef®cient antioxidant, in its reduced form of ubiquinol 10 (Matthews et al., 1998) .
Materials and methods

Subjects
The study was performed with 13 patients affected by several forms of MD diagnosed at the Department of Neuroscience, University of Pisa. The diagnosis of mitochondrial disease was established according to accepted clinical, morphological, biochemical and molecular genetic criteria (Schon et al., 1994; Moraes et al., 1995) . As far as clinical characteristics were concerned, eight subjects were affected by chronic progressive external ophthalmoplegia (CPEO), in one of them associated with ataxia, one by a complex picture of encephalomyopathy, one by myoneurogastrointestinal encephalopathy (MNGIE) syndrome and one by myoclonic epilepsy. From a molecular point of view, all patients but one (patient code MD1, mtDNA mutation unknown) carried a single or multiple large scale mtDNA deletion(s) ( Table I) . Patients did not follow any pharmacological therapy at the beginning of the study. In addition, 12 healthy individuals, matched for gender, age and smoking habit with MD patients, were selected as control subjects.
Heparinized peripheral blood samples were collected by venipuncture from individuals included in the study. All subjects were interviewed to ®ll in a detailed questionnaire on their personal data, occupational and medical history and lifestyle (smoking habit, diet, etc.); they had no previous history of exposure to toxic substances or recent X-ray examination. Informed consent for participation in the study was obtained from each subject and the study was approved by our local Ethical Committee.
A subset of 10 patients (six males and four females) gave consent to receive a 2 week therapy with CoQ10 (100 mg/day). Two blood samples were obtained from these individuals: the ®rst, prior to the treatment and the second at least 1 month after the ®rst sampling, i.e. 2 weeks after the end of the therapy.
Cytokinesis block micronucleus assay
The CBMN assay was performed according to the procedure described by Migliore et al. (1999) . Brie¯y two paired, independent lymphocyte cultures were set up in RPMI 1640 (Gibco BRL, Milan, Italy) supplemented with 20% foetal bovine serum (Gibco BRL), 1.5% phytohaemagglutinin (Gibco BRL) and 1% penicillin/streptomycin (Gibco BRL) for each whole blood sample collected. Cytochalasin B (Sigma, St Louis, MO) at a ®nal concentration of 6 mg/ml was added to each tube 44 h after the cultures were established, to block the cytokinesis of dividing cells. Binucleated lymphocytes were harvested 72 h after culture setting. Cells were treated with a hypotonic solution (0.075 M KCl) to lyse erythrocytes, pre®xed in 3:5 methanol:acetic acid, washed once with methanol and twice with 7:1 methanol:acetic acid ®xative and dropped onto cold glass slides. The slides were stained in 4% Giemsa solution or hybridized for the FISH analysis. Two thousand binucleated cells per experimental point were examined, following the scoring criteria adopted by the HUman MicroNucleus Project (Bonassi et al., 2001) . We evaluated the binucleated micronucleated cell frequency (BN MN ½) as number of binucleated lymphocytes containing one or more MN per 1000 binucleated cells. The ratio of per cent binucleated cells to total cells scored (BN %) was used as an index of cell proliferation in culture.
FISH analysis
A digoxigenin-labelled a-satellite DNA probe speci®c for the centromeres of all human chromosomes (Appligene Oncor, France) was used for FISH analysis. Pre-warmed slides were denatured in 70% formamide, 2Q SSC (saline sodium citrate buffer), pH 7.0, at 70°C for 2 min and then dehydrated via an ethanol series. The pancentromeric probe was denatured at 70°C for 5 min, placed on the slides and incubated overnight at 37°C in a moist box. Posthybridization washes were performed, ®rst in 2Q SSC, pH 7.0, for 5 min and then in 4Q SSC, 0.05% Tween 20 (SSCW) (Sigma-Aldrich, Italy) for 5 min. Slides were then incubated with three antibodies: mouse anti-digoxigenin (Boehringer Mannheim, Italy), TRITC-conjugated rabbit anti-mouse and TRITC-conjugated goat anti-rabbit (Sigma-Aldrich, Italy). Antibodies were diluted in immunological buffer (4Q SSC with 5% non-fat dry milk) and alternately incubated for 30 min at 37°C. Each incubation step was followed by three 2 min washes in SSCW at 37°C. After dehydrating through an ethanol series, slides were counterstained with 0.5 mg/ml DAPI (Sigma-Aldrich, Italy) dissolved in glycerol/DABCO antifade solution.
Preparations were analyzed on a¯uorescence microscope equipped with a bandpass ®lter for simultaneous visualization of TRITC and DAPI¯uores-cence. A total of 100 unequivocal MN contained in binucleated cells were examined for the presence of centromere-positive signals for each sample. Results were reported as percentage of centromere-positive MN (C+ MN %) and centromere-negative MN (C± MN %), respectively.
Single cell gel electrophoresis (Comet assay)
Human leukocytes were isolated from whole blood samples by means of two centrifugations in erythrocyte lysing buffer (NH 4 Cl, KHCO 3 and Na 2 EDTA) and resuspension in RPMI 1640 medium.
The modi®ed alkaline Comet assay was carried out according to the following procedure. Fully frosted microscope slides were covered with 1% normal melting point agarose in Ca 2+ -and Mg 2+ -free phosphate-buffered saline (PBS) (Sigma-Aldrich, Italy) and left in a dry place to solidify until further use. About 10 ml of leukocytes in PBS were mixed with 85 ml of 0.5% low melting point agarose (Agarose Wide Range; Sigma-Aldrich, Italy) at 37°C, under yellow light to prevent further induced damage to DNA. This cell suspension was rapidly pipetted on top of the ®rst agarose layer, covered with a coverslip and allowed to solidify at 4°C for 5 min. A ®nal layer of 0.5% low melting point agarose was added to the slide and left at 4°C for 10 min. The cells were then lysed by immersing the slides in a jar containing freshly prepared cold lysing solution [2.5 M NaCl, 100 mM Na 2 EDTA, 10 mM Tris, 10% DMSO with 1% Triton X-100 (Sigma-Aldrich, Italy), pH 10.0] for at least 1 h at 4°C.
A horizontal gel electrophoresis tank was ®lled with freshly made 4°C alkaline buffer (300 mM NaOH, 1 mM Na 2 EDTA, pH > 13). The slides were placed in this tank side by side with the agarose end facing the anode and with the electrophoresis buffer at a level of~0.25 cm above the slide surface. The slides were left in this high pH solution for 20 min to allow DNA unwinding and expression of alkali-labile sites. The DNA fragments were then separated by electrophoresis for 20 min at 25 V adjusted to 300 mA. After electrophoresis the slides were¯ooded with two changes of neutralization buffer (0.4 M Tris, pH 7.5) for 5 min each. This removed any remaining alkali and detergents, which could have interfered with staining. The slides were drained before being stained with 80 ml of 20 mg/ml ethidium bromide (Sigma-Aldrich, Italy).
Coded slides were viewed using an epi¯uorescence microscope (Nikon Eclipse E800) equipped with a ®lter for ethidium bromide visualization. Observations were made at a ®nal magni®cation of 600Q. Fifty randomly selected cells (25 cells from each of two replicate slides) per experimental point were evaluated using a semi-automated Komet Image Analysis System, Version 5.0 (Kinetic Imaging Ltd, Liverpool, UK). Results were reported as tail DNA percentage, a parameter describing the number of migrated fragments, represented by the¯uorescence intensity in the tail, expressed as the mean of the 50 cells scored.
Enzyme preparation and treatment for detection of oxidative DNA damage The alkaline version of the Comet assay modi®ed by the use of endo III and fpg was performed to detect oxidized pyrimidines and purines, respectively. The enzymes were kindly provided by Dr A.R.Collins (Aberdeen, UK).
Enzymes were diluted in enzyme buffer (PBS containing 40 mM Na 2 EDTA, 0.1 M KCl, 0.2 mg/ml BSA, 40 mM HEPES, pH 8.0; Sigma-Aldrich, Italy) and stored at ±80°C. Slides for enzyme treatment were removed from lysis solution and washed three times for 5 min each in enzyme buffer at 4°C. Then aliquots of 100 ml of enzyme solution, or buffer alone as a control, were placed on slides and covered with coverslips. Slides were put into a moist box to prevent desiccation and incubated at 37°C for 45 (endo III) or 30 min (fpg) before alkaline unwinding. The enzymes recognize and cut oxidized bases, producing DNA single-strand breaks (SSBs) that are expressed as fragments which migrate towards the anode during electrophoresis.
Statistical analysis
Multifactor analysis of variance was performed to statistically elaborate data obtained from the micronucleus assay, FISH analysis and the Comet assay in pre-treatment MD patients and healthy controls.
The comparisons between the mean frequencies of micronucleated binucleated cells and of cell migration by the Comet assay in MD patients before and after CoQ10 therapy were evaluated by using paired Student's t-test. The difference was considered signi®cant at the 95% con®dence level (P < 0.05).
Results
Demographic characteristics of the study population A summary of the demographic characteristics of the study population and of the clinical features of patients is reported in Table I . The MD patient group consisted of eight women and ®ve men, mean age 54.3 T 15.1 years (age range 27±74 years), while the control group included 12 healthy individuals, six males and six females, with a mean age comparable to that of patients (54.1 T 15.8). All subjects but two (one patient and one control) were non-smokers.
Cytokinesis block micronucleus assay and FISH analysis
The data presented in Table II indicate that the frequency of micronucleated binucleated lymphocytes ranged between 9.5 and 45.0½ in MD patients, whereas healthy individuals showed greatly lower values, between 1.0 and 21.0½. The average frequency of micronucleated cells in untreated MD patients (25.1 T 10.3½), after adjusting for confounding factors, was clearly different (P << 0.001) from that of healthy controls (8.8 T 5.3½). A signi®cant age-related increase in spontaneous MN frequency was observed when considering all samples (P < 0.01). FISH analysis, performed employing pancentromeric DNA probes, revealed a prevalence of centromere-containing MN (C+ MN %= 66.8 T 7.2%) in patients, derived from loss of entire chromosomes or of centric fragments. Controls presented a lower frequency of C+ MN (61.4 T 5.9%), but this difference did not reach statistical signi®cance (P = 0.0617). Table III reports the frequencies of micronucleated cells detected in a subset of 10 patients who had undergone a 2 week therapy with CoQ10, compared with the frequencies recorded in the same individuals at the time of ®rst blood sampling. The frequencies measured after treatment ranged from 7.5 to 34.0½. A signi®cant reduction (P < 0.05) in micronuclei occurrence (16.8 T 9.8½) in comparison with the baseline condition (27.0 T 10.9½) was observed. Table IV summarizes the results obtained with the Comet assay in leukocytes of patients and controls, expressed as tail DNA percentage. The multifactor analysis of variance did not reveal Effects of coenzyme Q10 therapy any signi®cant difference either in primary DNA damage, expressed as SSBs, between patients (8.3 T 1.9%) and controls (7.0 T 1.9%) or in SSBs induced by the enzymes at oxidized pyrimidines (8.5 T 6.3% in affected versus 6.6 T 4.5% in controls) or purines (6.8 T 4.8 versus 5.4 T 3.5%).
Comet assay
Finally, Table V shows Comet assay results for 10 patients before and after CoQ10 administration. Although a slight decrease in primary DNA damage and in enzyme-sensitive oxidized bases was observed, analysis of the data did not detect any statistical signi®cance.
Discussion
The present study provides the ®rst evidence of elevated baseline nDNA damage in peripheral blood lymphocytes of patients with MD. The CBMN assay detected a higher level of cytogenetic damage, expressed as frequency of micronucleated binucleated cells, in patients than in healthy matched controls. Moreover, multifactor analysis of variance showed that the micronuclei frequencies signi®cantly increased with chronological age of both patients and controls. This fact is consistent with the large age range of our study population. Several studies reported age as a relevant factor determining variations in spontaneous chromosomal instability. The increase in micronucleus frequencies with age may be explained by an accumulation of DNA damage as a consequence of a progressive decline in DNA repair capacity (Barale et al., 1998; Bolognesi et al., 1999; Bonassi et al., 2001) .
Micronuclei arise as a consequence of chromosome breakage and chromosome loss, triggered for example by oxidative stress and exposure to genotoxic agents. The use of FISH with probes speci®c for the centromere sequences of all human chromosomes allowed the evaluation of the origin of micronuclei in the study population. In patients a prevalence of micronuclei with a centromere signal was observed compared with healthy controls, however, this was not statistically signi®cant. Our data were in substantial agreement with other studies reporting percentages of~60% of micronuclei containing whole chromosomes lagging behind in anaphase in the general population (Catala Án et al., 1995; Scarpato et al., 1996) .
Endogenous oxidative stress is believed to play a key role in the onset and progression of MDs: it was found that intracellular H 2 O 2 and oxidative damage to DNA and lipids are signi®cantly higher in skin ®broblasts from patients with MD as compared with those of age-matched controls (Wei et al., 2001) . ROS are mainly released as a byproduct of electron transport during mitochondrial respiration (Turrens et al., 1985; Sohal and Sohal, 1991) . Furthermore, the mtDNA mutations found in MD may produce de®cient respiratory chain holoenzymes that block the correct¯ow of electrons, which may be preferentially transferred to molecular oxygen, thus enhancing ROS production during respiratory activity (Robinson, 1998) . Under ordinary conditions free radicals are removed by the action of scavenging enzymes and antioxidants before they can damage DNA, lipids and proteins. However, if the ratio of prooxidants to antioxidants increases, signi®cant damage occurs and may persist despite cellular repair pathways. At the molecular level the DNA damage introduced by ROS includes SSBs, double-strand breaks, abasic sites, formation of micronuclei and oxidized bases (von Sonntag, 1987; Lindahl, 1993; Demple and Harrison, 1994; Yakes and Van Houten, 1997) .
In order to evaluate oxidative DNA damage levels, in recent years a modi®ed Comet assay procedure, based on the use of lesion-speci®c enzymes that recognize and cut oxidized bases producing SSBs, was successfully introduced. In particular, endo III is speci®c for oxidized pyrimidines while fpg recognizes damaged purines, including 8-oxodG, a typical indicator of oxidative damage. In the present study this technique detected only slightly higher levels of SSB expression of both primary and oxidative DNA damage in affected patients compared with matched healthy controls. This ®nding is reinforced by data derived from the FISH analysis, showing a prevalence of MN including whole chromosomes and so not deriving from chromosome fragments generated by unrepaired primary DNA lesions. Furthermore, as fpg and endo III are not the only enzymes involved in the excision repair of oxidative damage and the detection of cut sites by these enzymes represents an indirect marker of oxidative damage, our results may represent an underestimation of the real levels of oxidized bases (Collins, 1999) . Another possibility is that fpg and endo III might cut only a fraction of the oxidized DNA sites, because of steric interference. It has been argued that free radicals may attack DNA producing clusters of oxidized lesions, which may be considered by the enzymes as a single cut site (Gedik et al., 1998) . A further aim of our work was the assessment of the effects that a 2 week therapy with CoQ10 may have at the cellular level on the variation in nDNA damage in patients exposed to elevated levels of endogenous oxidative stress. Despite great strides in our understanding of the biochemical and molecular causes of MD, therapy for these devastating disorders remains inadequate: the goals of treatment are, at present, alleviation of the symptoms and slowing down of the progression of the disease. Several attempts have been made by administering drugs either to increase respiratory chain ef®ciency or to minimize deleterious consequences of the altered cell metabolism, such as excessive cytoplasmic acidi®cation or membrane lipid peroxidation. To counteract the effects of oxidative stress, several oxygen radical scavengers have been utilized, most commonly CoQ10. CoQ10 is an endogenously synthesized provitamin located in the inner mitochondrial membrane where, realizing an interaction between speci®c enzyme complexes, it acts as an essential cofactor of the mitochondrial respiratory chain (Crane et al., 1993) . CoQ10 seems to have membrane-stabilizing properties and, in its reduced form (ubiquinol 10), an ef®cient free radical scavenging action (Beyer et al., 1987; Ernster and Dallner, 1995) . A recent study, using the alkaline Comet assay, showed that lymphocytes treated in vitro with CoQ10 were protected from DNA damage, in terms of SSBs and alkali-labile sites (Tomasetti et al., 1999) . These data seem to indicate that CoQ10 is somehow involved in the reduction in primary DNA damage. 
Effects of coenzyme Q10 therapy
Cytogenetic damage was assessed in the peripheral blood lymphocytes of a subset of 10 patients with different forms of MD before the onset of CoQ10 therapy and after treatment completion (post-treatment). Supplementation of CoQ10 for 2 weeks resulted in a consistent decrease in the mean frequency of damaged cells. This ®nding suggests a protective effect of CoQ10 with respect to DNA damage. On the other hand, the Comet assay detected only a slightly different distribution between patients and controls of spontaneous SSBs and of SSBs induced by enzymes at oxidized bases. A non-signi®cant tendency for a reduction in the levels of spontaneous or induced SSBs was measured in patients after CoQ10 administration. Moreover, remarkable inter-individual differences in therapy response were observed with this technique. These observations probably re¯ect differences in the individual characteristics of patients, severity of the disease, regimen and nutritional status and possibly in the rates of absorption and/or clearance of CoQ10 from the blood circulation. Indeed, in general, treatment may be bene®cial and immediately recorded in some individuals or may take a few months to be noticed. In other cases the bene®ts of treatment may never be seen, but the treatment may be effective in delaying or stopping progression of the disease, whereas some patients may not bene®t from the therapy. Several reports found both clinical and biochemical improvements after treatment with CoQ10 in patients with known MDs (Bresolin et al., 1988; Tarnopolsky and Beal, 2001 ). CoQ10 improved lactate/pyruvate in some patients with MD and oxygen consumption in a patient with MELAS. In contrast, no rigorously controlled therapeutic trial has yet been conducted and one of the larger trials on MDs found that CoQ10 plus several antioxidant vitamins resulted in a 3-fold increase in serum CoQ10 concentration, with no measurable improvements in oxidative metabolism (Matthews et al., 1993) .
It cannot be ruled out that the negative results obtained with the Comet assay in our study may be due to a limited sensitivity of our experimental system. Other studies performed using both the MN test and Comet assay did not ®nd correlating results (Gutierrez et al., 1998; Vijayalaxmi et al., 1998) . Some authors explained this by remarking that the CBMN procedure deals with lymphocytes, which represent only a minor fraction of white blood cells, while all leukocytes are analyzed in the Comet assay. Indeed, a certain variability among leukocyte populations and individual cells belonging to the same population exists in ROS release within the cell and in their repair capacity (Collins et al., 1995) . Thus, the negative results of the Comet assay reported in the present work may be due to a variation not only among individual subjects, but also among white blood cell types in the liberation of free radicals within the cell or in their ability to attack DNA and in cellular antioxidant protection (Green et al., 1994; Collins et al., 1995; Vijayalaxmi et al., 1998) .
In conclusion, our work suggests a possible contribution of oxidative stress to elevated levels of chromosome damage found in MD patients. We are aware that the small number of cases included in our study may represent a weakness, but this re¯ects the limited availability of patients, due to the low frequency of MDs observed in the general population (1 case in every 8500 individuals, as reported by Chinnery and Turnbull, 2001 ). Furthermore, the protective effect of CoQ10 seems to indicate an involvement of free radicals in cytogenetic alterations. Whether this protection is due to the antioxidant function of CoQ10 or to its action as a cofactor in the respiratory chain remains to be investigated by further studies.
